???global.info.a_carregar???
Identification

Personal identification

Full name
Jocelyne Demengeot

Author identifiers

Ciência ID
3A12-B260-A36C
ORCID iD
0000-0002-4761-614X
Projects

Grant

Designation Funders
2005/06 - 2007/07 Componentes da inflamação na biologia de Células T reguladoras e na prevenção de doenças auto-imunes
Provided by PTCRIS: POCI/SAU-MMO/58192/2004
POCI/SAU-MMO/58192/2004
Fundação Calouste Gulbenkian, Portugal

Instituto Gulbenkian de Ciência, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded

Contract

Designation Funders
2023/01/01 - 2024/06/30 Unravelling the (T)Regulatory power of Glycans in Autoimmunity: mechanism and potential clinical applications
2022.01422.PTDC
10.54499/2022.01422.PTDC
Instituto de Astrofísica e Ciências do Espaço, Portugal

Instituto Gulbenkian de Ciência, Portugal

Centro Hospitalar Universitário de Santo António, Portugal
 Fundação para a Ciência e a Tecnologia
Ongoing
2015/01/01 - 2017/12/31 Regulação das respostas dos centros germinativos em doentes alérgicos
HMSP-ICT/0034/2013
Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal

Fundação Calouste Gulbenkian, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2009/01/01 - 2012/06/30 Lúpus e sua compensação em familiares não afectados por regulação de células T
PIC/IC/82746/2007
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal

Universidade de Trás-os-Montes e Alto Douro Centro de Investigação e de Tecnologias Agro-Ambientais e Biologicas, Portugal

Instituto Gulbenkian de Ciência, Portugal

Hospital Geral de Santo António SA, Portugal

Associacao de Doentes com Lupus, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2008/06/16 - 2012/02/14 Nutracêuticos: que papel na prevenção na doença crónica? - contributo para a fundamentação de uma nova opção terapêutica -
PTDC/SAU-OSM/66323/2006
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal

Universidade de Lisboa Faculdade de Medicina, Portugal

Hospital Pulido Valente, Portugal

Fundação Calouste Gulbenkian, Portugal

Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal

Universidade Nova de Lisboa Medical School, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2005/03/20 - 2008/06/30 Lupus em humanos e em modelo murino: reportorio de auto-anticorpos e celulas T reguladoras
POCI/SAU-MMO/59913/2004
Hospital do Divino Espírito Santo de Ponta Delgada EPE, Portugal

Universidade de Trás-os-Montes e Alto Douro Centro de Investigação e de Tecnologias Agro-Ambientais e Biologicas, Portugal

Instituto Gulbenkian de Ciência, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2005/06/01 - 2007/07/31 Genética da resposta imune inata na diabetes tipo 1 murina
POCI/SAU-MMO/62964/2004
Provided by PTCRIS: POCI/SAU-MMO/62964/2004
Fundação Calouste Gulbenkian, Portugal

Instituto Gulbenkian de Ciência, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2005/05/01 - 2007/01/31 Indução de tolerância em doenças autoimunes: reprogramar o sistema imunitário com anticorpos monoclonais.
POCI/SAU-MMO/55974/2004
Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal

Fundação Calouste Gulbenkian, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
Outputs

Publications

Book
  1. Garcês, S.; Demengeot, J.; Demengeot, Jocelyne. The Immunogenicity of Biologic Therapies. 2017.
    10.1159/000478077
Book chapter
  1. da Silva Domingues, Vital; Caramalho, Iris; Bergman, Marie-Louise; Demengeot, Jocelyne. Corresponding author: Demengeot, Jocelyne. "Adoptive Transfer and Bone Marrow Chimera Models to Analyze Treg Function and Differentiation". In Methods in Molecular Biology, 15-29. Springer US, 2023.
    10.1007/978-1-0716-2647-4_2
  2. Garcês, Sandra; Demengeot, Jocelyne. "The Immunogenicity of Biologic Therapies". In Current Problems in Dermatology, 37-48. S. Karger AG, 2017.
    10.1159/000478077
  3. Hori, Shohei; Demengeot, Jocelyne; Bandeira, Antonio; Coutinho, Antonio. "Cancer Immunity: A Problem of Self-Tolerance". In Cancer and Autoimmunity, 337-342. Elsevier, 2000.
    10.1016/b978-044450331-2/50035-7
Conference poster
  1. Cruz, Carlos; Buga, Carolina C.; Kosack, Lindsay; Alenquer, Marta; Demengeot, Jocelyne; Amorim, Maria Joao; Soares, Claudio M.; Vicente, João B.; Lousa, Diana. "Antibodies elicited by rationally-designed FP-based immunogenic protein have high-affinity for the SARS-CoV-2 spike protein". Paper presented in VIII Encontro de Jovens Investigadores em Biologia Computacional Estrutural, Coimbra, 2021.
Journal article
  1. Qian Wu; Carlos, A R; Faouzi Braza; Marie-Louise Bergman; Jamil Kitoko; Patricia Bastos Amador; Eloy Cuadrado; et al. "Ferritin heavy chain supports stability and function of the regulatory T cell lineage". The EMBO Journal (2024): http://dx.doi.org/10.1038/s44318-024-00064-x.
    10.1038/s44318-024-00064-x
  2. Caramalho, Iris; Matoso, Paula; Ligeiro, Dário; Paixão, Tiago; Sobral, Daniel; Fitas, Ana Laura; Limbert, Catarina; Demengeot, Jocelyne; Penha-Gonçalves, Carlos. Corresponding author: Caramalho, Iris. "The rare DRB1*04:08-DQ8 haplotype is the main HLA class II genetic driver and discriminative factor of Early-onset Type 1 diabetes in the Portuguese population". Frontiers in Immunology 14 (2024): http://dx.doi.org/10.3389/fimmu.2023.1299609.
    10.3389/fimmu.2023.1299609
  3. Barroso-Batista, João; Pedro, Miguel Filipe; Sales-Dias, Joana; Pinto, Catarina Jesus Garcia; Pereira, Helena; Demengeot, Jocelyne; Gordo, Isabel; Xavier, Karina. "Specific Eco-Evolutionary Contexts in the Mouse Gut Reveal <i>Escherichia coli</i> Metabolic Versatility". SSRN Electronic Journal (2019): http://dx.doi.org/10.2139/ssrn.3433809.
    10.2139/ssrn.3433809
  4. Meehan, T.F.; Chen, C.-K.; Koscielny, G.; Relac, M.; Wilkinson, P.; Flicek, P.; Parkinson, H.; et al. "INFRAFRONTIER-providing mutant mouse resources as research tools for the international scientific community". Nucleic Acids Research 43 D1 (2015): D1171-D1175. http://www.scopus.com/inward/record.url?eid=2-s2.0-84941108631&partnerID=MN8TOARS.
    10.1093/nar/gku1193
  5. S Garcês; M Antunes; E Benito-Garcia; J Canas-Silva; L Aarden; J Demengeot. "A1.79 A preliminary algorithm introducing immunogenicity assessment in the management of RA patients receiving biotechnological therapies". Annals of the Rheumatic Diseases 73 Suppl 1 (2014): A35.1-A35. https://doi.org/10.1136%2Fannrheumdis-2013-205124.78.
    10.1136/annrheumdis-2013-205124.78
  6. S. Garcês; J. Canas-da-Silva; L. Aarden; J. Demengeot. "FRI0092 New algorithm to approach ra patients receiving biologic therapies: Introducing immunogenicity assessment in the eular guidelines". Annals of the Rheumatic Diseases 71 Suppl 3 (2014): 340.2-340. https://doi.org/10.1136%2Fannrheumdis-2012-eular.2549.
    10.1136/annrheumdis-2012-eular.2549
  7. S. Garcês; J. Demengeot; J. Canas-da-Silva; L. Aarden. "AB1297 Bridging ELISA as a secreening assay to monitor immunogenicity in routine clinical practice". Annals of the Rheumatic Diseases 71 Suppl 3 (2014): 711.17-711. https://doi.org/10.1136%2Fannrheumdis-2012-eular.1293.
    10.1136/annrheumdis-2012-eular.1293
  8. S. Garcês; J. Freitas; J. Canas-Silva; L. Aarden; J. Demengeot. "FRI0188 The impact of immunogenicity on drug safety profile". Annals of the Rheumatic Diseases 72 Suppl 3 (2014): A436.1-A436. https://doi.org/10.1136%2Fannrheumdis-2013-eular.1315.
    10.1136/annrheumdis-2013-eular.1315
  9. S. Garcês; M. Antunes; E. Benito-Garcia; J. Canas-Silva; L. Aarden; J. Demengeot. "FRI0189 A preliminary algorithm introducing immunogenicity assessment in the management of ra patients receiving biotechnological therapies". Annals of the Rheumatic Diseases 72 Suppl 3 (2014): A436.2-A436. https://doi.org/10.1136%2Fannrheumdis-2013-eular.1316.
    10.1136/annrheumdis-2013-eular.1316
  10. S. Garcês; J. Demengeot; E. Benito-Garcia. "SAT0479 Clinical impact of immunogenicity of infliximab, adalimumab and etanercept: A systematic review of the literature with a meta-analysis". Annals of the Rheumatic Diseases 71 Suppl 3 (2014): 634.3-635. https://doi.org/10.1136%2Fannrheumdis-2012-eular.3425.
    10.1136/annrheumdis-2012-eular.3425
  11. Mathieu, C.; Overbergh, L.; Badenhoop, K.; Bingley, P.J.; Dayan, C.M.; Demengeot, J.; Dotta, F.; et al. "The story of NAIMIT - A framework 7 project on type 1 diabetes". European Endocrinology 10 2 (2014): 100-105. http://www.scopus.com/inward/record.url?eid=2-s2.0-84920275834&partnerID=MN8TOARS.
  12. Carneiro, J.; Leon, K.; Caramalho, Í.; Van Den Dool, C.; Gardner, R.; Oliveira, V.; Bergman, M.-L.; et al. "When three is not a crowd: A Crossregulation Model of the dynamics and repertoire selection of regulatory CD4<sup>+</sup>T cells". Immunological Reviews 216 1 (2007): 48-68. http://www.scopus.com/inward/record.url?eid=2-s2.0-33947192440&partnerID=MN8TOARS.
    10.1111/j.1600-065X.2007.00487.x
  13. Zelenay, S.; Demengeot, J.; Zelenay, Santiago; Demengeot, Jocelyne. "Comment on "Cutting edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4 +CD25+ T regulatory cells" [4]". Journal of Immunology 177 4 (2006): 2036-2037. http://www.scopus.com/inward/record.url?eid=2-s2.0-33746879581&partnerID=MN8TOARS.
    10.4049/jimmunol.177.4.2036-a
  14. Coutinho A; Caramalho I; Seixas E; Demengeot J; Coutinho, A.; Caramalho, I.; Seixas, E.; Demengeot, Jocelyne; Demengeot, J.. "Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.". Current topics in microbiology and immunology 293 (2005): http://europepmc.org/abstract/med/15981475.
    Published • 10.1007/3-540-27702-1_3
  15. Braun, D.; Geraldes, P.; Demengeot, J.; Braun, D. "Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice". Journal of Autoimmunity 20 1 (2003): 15-25. http://www.scopus.com/inward/record.url?eid=2-s2.0-0037320208&partnerID=MN8TOARS.
    10.1016/S0896-8411(02)00109-9
  16. Demengeot, J.; Hori, S.. "Keeping hopes high. Workshop on the molecular and genetic basis of autoimmune diseases: SLE and RA". EMBO Reports 4 11 (2003): 1033-1037. http://www.scopus.com/inward/record.url?eid=2-s2.0-0346873030&partnerID=MN8TOARS.
    10.1038/sj.embor.7400012
  17. Hori, S.; Carvalho, T.L.; Demengeot, J.; Hori, Shohei; Carvalho, Thiago L.; Demengeot, Jocelyne. "CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice". European Journal of Immunology 32 5 (2002): 1282-1291. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036107373&partnerID=MN8TOARS.
    10.1002/1521-4141(200205)32:5&lt;1282::AID-IMMU1282&gt;3.0.CO;2-#
  18. Braun, D.; Caramalho, I.; Demengeot, J.; Braun, Déborah; Caramalho, Iris; Demengeot, Jocelyne. "IFn-a/ß enhances BCR-dependent B cell responses". International Immunology 14 4 (2002): 411-419. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036206908&partnerID=MN8TOARS.
    10.1093/intimm/14.4.411
  19. Taccioli, G.E.; Gottlieb, T.M.; Blunt, T.; Priestley, A.; Demengeot, J.; Mizuta, R.; Lehmann, A.R.; et al. "Ku80: Product of the XRCC5 gene and its role in DNA repair and V(D)J recombination". Science 265 5177 (1994): 1442-1445. http://www.scopus.com/inward/record.url?eid=2-s2.0-0028025020&partnerID=MN8TOARS.
    10.1126/science.8073286
  20. Demengeot, J.; Jacquemier, J.; Torrente, M.; Blangy, D.; Berebbi, M.; Demengeot, J; Jacquemier, J; et al. "Pattern of polyomavirus replication from infection until tumor formation in the organs of athymic nu/nu mice". Journal of Virology 64 11 (1990): 5633-5639. http://www.scopus.com/inward/record.url?eid=2-s2.0-0025036314&partnerID=MN8TOARS.
    10.1128/jvi.64.11.5633-5639.1990
Preprint
  1. Iris Caramalho; Paula Matoso; Dário Ligeiro; Tiago Paixão; Daniel Sobral; Ana Laura Fitas; Catarina Limbert; Jocelyne Demengeot; Carlos Penha-Gonçalves. "The rare DRB1*04-DQ8 haplotype is the main discriminative HLA class II genetic driver of Early-Onset Type 1 Diabetes in the Portuguese population". 2023. https://doi.org/10.1101/2023.07.23.23293034.
    10.1101/2023.07.23.23293034
  2. F. Viana J; Bergman M; A. Gonçalves L; Duarte N; C. Borges P; Diwo C; Castro R; et al. "Population homogeneity for the antibody response to COVID-19 Comirnaty vaccine is only reached after the second dose". 2021. http://europepmc.org/abstract/PPR/PPR302374.
    10.1101/2021.03.19.21253680
Thesis / Dissertation
  1. "Robust tolerance out of versatile regulatory Tcells". PhD, Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica, 2020.
  2. "Thymic activities in the establishment of tumor immune tolerance". PhD, Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica, 2020.
  3. "Origin and function of regulatory T cells". PhD, Fundação da Faculdade de Ciências da Universidade de Lisboa, 2007.

Other

Other output
  1. Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of immune evasion affecting antibody but not ACE2 binding. 2021. Marta Alenquer; Filipe Ferreira; Diana Lousa; Mariana Valério; Mónica Medina-Lopes; Marie-Louise Bergman; Juliana Gonçalves; et al. https://doi.org/10.1101/2021.04.22.441007.
    10.1101/2021.04.22.441007
  2. Interruption of thymic activity in adults improves responses to tumor immunotherapy. 2020. José Almeida-Santos; Marie-Louise Bergman; Inês Amendoeira Cabral; Jocelyne Demengeot. https://doi.org/10.1101/2020.01.08.899484.
    10.1101/2020.01.08.899484
  3. A weak Foxp3 hypomorph enhances spontaneous and therapeutic immune surveillance of cancer in mice. 2019. José Almeida-Santos; Marie-Louise Bergman; Inês Amendoeira Cabral; Vasco Correia; Íris Caramalho; Jocelyne Demengeot. https://doi.org/10.1101/570671.
    10.1101/570671
Distinctions

Other distinction

2012 European Research Council panel member
European Research Council, Belgium